Lite Strategy (LITS) Total Liabilities (2011 - 2026)
Lite Strategy (LITS) posted Total Liabilities of $952000.0 for Q1 2026, down 12.42% on a QoQ basis from $1.1 million in Q4 2025, and down 23.1% year-over-year from $1.2 million in Q1 2025.
Analysis
Lite Strategy (LITS) Total Liabilities (2011 - 2026) Analysis & Trends
Lite Strategy has reported Total Liabilities for 16 years, with the latest figure at $952000.0 in Q1 2026.
- On a quarterly basis, Total Liabilities fell 23.1% year-over-year to $952000.0 in Q1 2026; TTM through Mar 2026 was $952000.0, a 23.1% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, down 83.79% from the prior year.
- Total Liabilities was $952000.0 for Q1 2026 at Lite Strategy, down from $1.1 million in the prior quarter.
- The five-year high for Total Liabilities was $126.6 million in Q1 2022, with the low at $952000.0 in Q1 2026.
- Average Total Liabilities over 5 years is $44.2 million, with a median of $19.0 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities gained 0.64% in 2022, then sank 93.88% in 2025.
- Over 5 years, Total Liabilities stood at $99.2 million in 2022, then tumbled by 80.8% to $19.0 million in 2023, then plunged by 87.99% to $2.3 million in 2024, then tumbled by 52.47% to $1.1 million in 2025, then fell by 12.42% to $952000.0 in 2026.
- The last three Total Liabilities figures came in at $952000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | 952,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 952,000.00 |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 8.36 Mn |
| Mar 31, 2024 | 20.23 Mn |
| Dec 31, 2023 | 19.05 Mn |
| Sep 30, 2023 | 19.89 Mn |
| Jun 30, 2023 | 96.19 Mn |
| Mar 31, 2023 | 99.83 Mn |
| Dec 31, 2022 | 99.23 Mn |
| Sep 30, 2022 | 126.28 Mn |
| Jun 30, 2022 | 125.43 Mn |
| Mar 31, 2022 | 126.62 Mn |
| Dec 31, 2021 | 136.13 Mn |
| Sep 30, 2021 | 142.05 Mn |
| Jun 30, 2021 | 124.63 Mn |